Related posts

Inflation data and hike fears pressure stocks
Investor Insights

This summary was created by AI, based on 3 opinions in the last 12 months.

Dexcom (DXCM-Q) has been hit hard by investor fears over the potential impact of new weight loss drugs on demand for diabetes monitoring products. However, the sell-off is seen as overdone by analysts, with the company still growing, financially strong, and maintaining a robust market share. Best Buy's decision to sell its products indicates an expanding footprint. While the company is hard to compare with smaller rival WELL, DXCM is seen as worth holding due to its safety and valuation standpoint.

Consensus
Hold
Valuation
Undervalued
BUY ON WEAKNESS
Dexcom
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free

0
DON'T BUY
Dexcom

Does well when (sadly) diabetes is booming. The fear is that drugs develop from Novo Nordisk and Eli Lilly will cut down on diabetes. He tends to agree. Be careful here.

0
DON'T BUY
Dexcom
The Saudi/OPEC oil cut today

He regrets he didn't sell some of his oil holdings today. He doesn't see the price of oil moving up from here, but will move down.

0
COMMENT
Dexcom
Shares are expensive, but their diabetes machine is the best. Likes it, but these expensive stocks have had a hard time in this market.
0
COMMENT
Dexcom
They make blood sugar monitors used by diabetics. One of the best growth stocks of the last 5 years, from $60 from end-2017 to $659 last November. Since then, it's plunged to $462. Today, the company reported Q4 sales were in line and issued cautious guidance for 2022. They under-promise and over-delivered.
0
BUY
Dexcom
They make blood-sugar monitor for diabetics. He has long liked this. Performed well last year until Covid delayed the development in their new device which happened when the market lost interest in health stocks. But a few months ago, it started to come back. Yesterday, they reported a mixed quarter with a nice revenue beat, but small earnings miss, yet offered conservative guidance expand overseas. It fell 5% today. Likes that they're spending money to grow and their conservative nature.
0
COMMENT
Dexcom
The stock got overheated and has pulled back. It's up over 50% YTD. The quarter they reported in late-October was imperfect with a big earnings beat but a smaller sales beat compared to previous quarter. Their new blood sugar monitor is rolling out in only some key markets in 2021, not in all key ones until 2023. Both factors led to the stock getting hurt. Today, management guided for 15-20% growth through 2025, but fell short of expectations. The stock sold off today.
0
HOLD
Dexcom
Medical devices. Monitor diabetes. Recurring revenue from disposable sensors. M&A potential. Really likes the sector. Stick with it.
0
Showing 1 to 8 of 8 entries
  • «
  • 1
  • »

Dexcom(DXCM-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 3

Stockchase rating for Dexcom is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Dexcom(DXCM-Q) Frequently Asked Questions

What is Dexcom stock symbol?

Dexcom is a American stock, trading under the symbol DXCM-Q on the NASDAQ (DXCM). It is usually referred to as NASDAQ:DXCM or DXCM-Q

Is Dexcom a buy or a sell?

In the last year, 3 stock analysts published opinions about DXCM-Q. 1 analyst recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Dexcom.

Is Dexcom a good investment or a top pick?

Dexcom was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Dexcom.

Why is Dexcom stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Dexcom worth watching?

3 stock analysts on Stockchase covered Dexcom In the last year. It is a trending stock that is worth watching.

What is Dexcom stock price?

On 2024-02-29, Dexcom (DXCM-Q) stock closed at a price of $114.95.